Connect with us

Latest

Low-dose aspirin can reduce the risk of ICU admission and death of Covid-19, researchers say

Published

on

[ad_1]

Cheap and widely available pills also keep patients out of the ICU and can reduce the risk of death, probably preventing small blood clots, a team at George Washington University was reported in a study published in the journal Anesthesia & Analgesia.

Aspirin is particularly attractive because it is one of the most widely available over-the-counter medications. Its cost, at only cents per dose, is minuscule compared to other anti-covide drugs in use such as remdesivir, which can generate thousands of dollars for a typical course of treatment.

Aspirin can help prevent blood clots, which is why people who have had a heart attack are often advised to take an aspirin every day.

“The reason we started looking at aspirin and Covid is because in the spring we realized that all of these patients started having a lot of thrombotic complications or a lot of blood clots that have formed throughout the body,” he said. Dr. Jonathan Chow, an adjunct professor of anesthesiology and critical care medicine at the George Washington School of Medicine and Health Sciences, told CNN.

“That’s why we thought the use of an antiplatelet agent or an anticoagulant, like aspirin, might be helpful in COVID-19,” Chow said.

The team examined the records of 412 patients admitted to various U.S. hospitals between March and July 2020. Approximately 24% of patients received aspirin within 24 hours of hospital admission or in the previous seven days. to hospital admission. But the majority, 76%, did not receive the drug. The researchers found that aspirin use was associated with a 44% reduction in mechanical ventilation, a 43% reduction in ICU admission, and a 47% reduction in hospital mortality.

Other studies have made similar findings. One study, published in the journal PLOS One, examined more than 30,000 U.S. veterans with Covid-19 and found that those who already took aspirin had half the risk of dying than those who did not prescribe the daily pills.

Chow warned that a limitation of his team’s new study was that it analyzed medical records and did not randomly assign patients to take aspirin or placebo.

He pointed out the Recovery test in the UK, which investigates aspirin and Covid-19 in a gold standard randomized controlled trial, as the highest arbiter to see if aspirin definitely improves outcomes compared to patients who do not take the drug.

.

[ad_2]

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *